CRISP: First Real-World Evidence of NSCLC Stage I, II and III in Germany – AIO-TRK-0315 11. November 2022 Stuschke M, Eberhardt WEE, Passlick B, Groeschel A, Christopoulos P, Reck M, et al. 2022. Abstract Book WCLC 2022, p. 579 EP05.01-030 Download Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): Real-World Evidence of NSCLC Stage I, II and III in Germany – AIO-TRK-0315. Passlick B, Stuschke M, Gröschel A, Christopoulos P, Reck M, Grah C, et al. 2022. Zentralbl Chir. 2022;147(S 01):S47–8. Weiterlesen Clinical research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): Real-world evidence of NSCLC patients treated with radiochemotherapy in Germany – AIO-TRK-0315. Eberhardt WEE, Passlick B, Stuschke M, Groeschel A, Christopoulos P, Reck M, et al. 2022. Annals of Oncology. 2022 Sep;33(Supplement 7):S988. Download… Weiterlesen